EC approves MabThera for first-line NHL

The EC granted marketing approval for MabThera ( Rituxan) rituximab from Roche (SWX:ROCZ) in combination with chemotherapy for first line use to treat indolent non-Hodgkin's lymphoma (NHL). Rituximab ...